How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 25, Issue 5, 2013, Pages 573-578

  Gafos, Mitzy ^a,b   Mzimela, Misiwe A ^a,c   Ndlovu, Hlengiwe B ^a,c   McCormack, Sheena ^b   McGrath, Nuala ^a,d  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF ZULULAND   (South Africa)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

access; HIV; microbicides; South Africa; women

Indexed keywords

ANTIRETROVIRUS AGENT; MICROBICIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONDOM; DRUG EFFICACY; FEMALE; HEALTH CARE ACCESS; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MALE; PRIORITY JOURNAL; RURAL AREA; SOUTH AFRICA;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; CONDOMS; FEMALE; FOCUS GROUPS; HIV INFECTIONS; HUMANS; MIDDLE AGED; RURAL POPULATION; SAFE SEX; SOUTH AFRICA; WOMEN; YOUNG ADULT;

EID: 84876148318     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540121.2012.722604     Document Type: Article

References (35)

1. Abdool-Karim, Q., Abdool Karim, S.S., Frohlich, J.A., Grobler, A.C., Baxter, C., Mansoor, L.E., and Taylor, D. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 329 (5996): 1168-1174.
2. Abdool-Karim, S., Richardson, A., Ramjee, G., Hoffman, F., Chirenje, M., Taha, T., and Soto-Torres, L. 2011. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS, 25 (7): 957-966.
3. Baeten, J.M., Donnell, D., Ndase, P., Mugo, N.R., Campbell, J.D., Wangisi, J., Celum, C. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women [Research Support, Non-U.S. Gov't]. The New England Journal of Medicine, 367 (5), 399-410. doi: 10.1056/NEJMoa1108524
4. Bailey, R.C., Moses, S., Parker, C.B., Agot, K., Maclean, I., Krieger, J.N., and Ndinya-Achola, J.O. 2007. Male circumcision for HIV prevention in young men in Kismu, Kenya: A randomised controlled trial. The Lancet, 369 (9562): 643-656.
5. Bärnighausen, T., Tanser, F., Gqwede, Z., Mbizana, C., Herbst, K., and Newell, M. 2008. High HIV incidence in a community with high HIV prevalence in rural South Africa: Findings from a prospective population-based study. AIDS, 22: 139-144.
6. Celum, C., & Baeten, J.M. 2012. Tenofovir-based pre-exposure prophylaxis for HIV prevention: Evolving evidence. Current Opinion in Infectious Diseases, 25 (1), 51-57. doi: 10.1097/QCO.0b013e32834ef5ef
7. Chimbindi, N.Z., McGrath, N., Herbst, K., San Tint, K., & Newell, M.L. 2010. Socio-demographic determinants of condom use among sexually active young adults in rural KwaZulu-Natal, South Africa. The Open AIDS Journal, 4, 88-95. doi: 10.2174/1874613601004010088
8. FACTS. 2012. Facts consortium. Retrieved from http://www.facts- consortium.co.za/
9. Feldblum, P.J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., Rountree, W. 2008. SAVVY vaginal gel (C31G) for prevention of HIV infection: A randomized controlled trial in Nigeria. PLoS One, 3 (1), e 1474. doi: 10.1371/journal.pone.0001474
10. Foss, A.M., Vickerman, P.T., Heise, L., & Watts, C.H. 2003. Shifts in condom use following microbicide introduction: Should we be concerned? AIDS, 17 (8), 1227-1237. doi: 10.1097/01.aids.0000060388.18106.43
11. Grant, R.M., Lama, J.R., Anderson, P.L., McMahan, V., Liu, A.Y., Vargas, L., Glidden, D.V. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England Journal of Medicine, 363 (27), 2587-2599. doi: 10.1056/NEJMoa1011205
12. Hoffman, S., Cooper, D., Ramjee, G., Higgins, J.A., & Mantell, J.E. 2008. Microbicide acceptability: Insights for future directions from providers and policy makers. AIDS Education and Prevention, 20 (2), 188-202. doi: 10.1521/aeap.2008.20.2.188
13. Horwood, J. 2007. Cellulose sulphate microbicide trial halted. The Lancet Infectious Diseases, 7 (3): 183
14. Maharaj, P., & Cleland, J. 2005. Risk perception and condom use among married Or cohabiting couples in KwaZulu-Natal, South Africa. International Family Planning Perspectives, 31 (1), 24-29.
15. Mantell, J.E., Myer, L., Carballo-Dieguez, A., Stein, Z., Ramjee, G., Morar, N.S., and Harrison, P.F. 2005. Microbicide acceptability research: Current approaches and future directions. Social Sciences and Medicine, 60 (2): 319-330.
16. McCormack, S., Ramjee, G., Kamali, A., Rees, H., Crook, A.M., Gafos, M., and Weber, J. 2010. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, double-blind, parallel-group trial. Lancet, 376 (9749): 1329-1337.
17. MDP. 2008. Microbicides Development Programme (MDP) update: MDP301 Phase III trial continues but one arm closes. Retrieved from http://www.mdp.mrc.ac.uk/ downloads/MDP-statement-14Feb08-v1%5B1%5D.2-FINAL.pdf
18. MTN. 2011a. MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. Retrieved from http://www.mtnstopshiv.org/node/3619
19. MTN. 2011b. MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. Retrieved from http://www.mtnstopshiv.org/node/3909
20. MTN. 2011c. VOICE (MTN-003). Microbicides trial network. Retrieved from http://www.mtnstopshiv.org/news/studies/mtn003
21. MTN. 2012. Phase III trial of dapivirine ring begins in Africa: ASPIRE testing new HIV prevention approach for women. Retrieved from http://www.mtnstopshiv.org/node/4546
22. Ngubane, N., Patel, D., Newell, M.L., Coovadia, H.M., Rollins, N., Coutsoudis, A., and Bland, R. 2008. Messages about dual contraception in areas of high HIV prevalence are not heeded. South African Medical Journal, 98 (3): 209-212.
23. Nunn, A., McCormack, S., Crook, A.M., Pool, R., Rutterford, C., & Hayes, R. 2009. Microbicides Development Programme: Design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention. Trials, 10 (99). doi: 10.1186/1745-6215-10-99. Retrieved from http://www.trialsjournal.com/content/10/1/99
24. Omar, R., & Bergeron, M.G. 2011. The future of microbicides. International Journal of Infectious Diseases, 15 (10), e 656-660. doi: 10.1016/j.ijid.2011.05.001
25. Peterson, L., Nanda, K., Opoku, B.K., Ampofo, W.K., Owusu-Amoako, M., Boakye, A.Y., Dorflinger, L. 2007. SAVVY (C31G) gel for prevention of HIV infection in women: A Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One, 2 (12), e 1312. doi: 10.1371/journal.pone.0001312
26. Schwartz, J.L., Rountree, W., Kashuba, A.D., Brache, V., Creinin, M.D., Poindexter, A., and Kearney, B.P. 2011. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One, 6 (10): e25974
27. Skoler-Karpoff, S.R., Ahmed, G., Altini, K., Plagianos, L., Friedland, M., Govender, B., and Lahteenmaki, P. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. The Lancet, 372 (9654): 1977-1987.
28. Tanser, F., Hosegood, V., Bärnighausen, T., Herbst, K., Nyirenda, M., Muhwava, W., and Newell, M. 2007. Cohort profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. International Journal of Epidemiology, 37 (5): 956-962.
29. Thigpen, M.C., Kebaabetswe, P.M., Paxton, L.A., Smith, D.K., Rose, C.E., Segolodi, T.M., Brooks, J.T. 2012. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.]. The New England Journal of Medicine, 367 (5), 423-434. doi: 10.1056/NEJMoa1110711
30. Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., FEM-PrEP Study Group. 2012a. The FEM-PrEP trial of emtricitabine/tenofovir disoproxil fumarate (Truvada) among African Women. Paper presented at the CROI, Seatle.
31. Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., Onyango, J. 2012b. Preexposure prophylaxis for HIV infection among African women. The New England Journal of Medicine, 367 (5), 411-422.
32. Vickerman, P., Watts, C., Delany, S., Alary, M., Rees, H., and Heise, L. 2006. The importance of context: Model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioural situation in 2 African settings. Sexually Transmitted Diseases, 33 (6): 397-405.
33. WHO. 2010. Preparing for access to PRO 2000 microbicide. Geneva: Author.
34. Williams, B.G., Abdool Karim, S.S., Karim, Q.A., & Gouws, E. 2011. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. Journal of Acquired Immune Deficiency Syndromes, 58 (2), 207-210. doi: 10.1097/QAI.0b013e3182253c19
35. Winch, P., Wagman, J.A., Malouin, R.A., & Mehl, G.L. 2000. Qualitative research for improved health programs: A guide to manuals for qualitative and participatory research on child health, nutrition, and reproductive health. (School of Hygiene and Public Health, Department of International Health, Johns Hopkins University, Ed.). Boston: Johns Hopkins University.